Can TMS Help With Anxiety, OCD, PTSD, or Bipolar Depression?

TMS is FDA-cleared for anxiety symptoms in adults who have major depressive disorder, on the BrainsWay (2021) and NeuroStar (2022) systems. In that group, anxiety typically improves alongside depression. TMS is not FDA-cleared for generalized anxiety disorder, panic disorder, or social anxiety on their own; small studies exist but there is no pivotal trial. If you have anxiety without depression, psychotherapy and medication remain the evidence-based first-line treatments, and any TMS would be off-label.

Yes, for one device. BrainsWay Deep TMS with the H7 coil was granted FDA marketing authorization for obsessive-compulsive disorder through the De Novo pathway in 2018, based on a multicenter sham-controlled trial in adults whose OCD had not responded adequately to prior treatment. Sessions target the medial prefrontal and anterior cingulate cortices and include brief symptom provocation. Other TMS devices are not cleared for OCD unless their labeling says so.

It is unproven. Several small randomized trials, including research within the Department of Veterans Affairs, have tested TMS for PTSD with different targets and frequencies; some showed benefit over sham and others did not. No TMS device is FDA-cleared for PTSD, so any use is off-label and usually not covered by insurance. Trauma-focused psychotherapies such as EMDR, prolonged exposure, and cognitive processing therapy remain the first-line treatments.

Only off-label, and with caution. Randomized trials of TMS for the depressive phase of bipolar disorder have had mixed results and small samples, and no device is FDA-cleared for bipolar disorder. TMS carries a small risk of triggering mania or hypomania, so it should not be given during a manic episode and, if used at all, requires a mood stabilizer and close monitoring. First-line treatments are mood-stabilizing medications and, for severe episodes, ECT.

Off-label means a clinician uses an FDA-cleared TMS device for a condition the device is not cleared to treat, such as PTSD or bipolar depression. This is legal, and physicians may do it when they judge the evidence and risks acceptable, but the manufacturer cannot promote that use, the supporting evidence is typically weaker or mixed, and insurance rarely pays. You should be told explicitly when a proposed treatment is off-label and give informed consent.

No. Consumer magnetic therapy products such as bracelets, mats, or static magnets are not TMS and have no evidence for anxiety or depression. TMS uses a powerful, rapidly changing electromagnetic field generated by a medical device, operated by trained staff under a physician's supervision, to induce electrical currents in specific brain regions. Only prescription TMS systems are FDA-cleared, and only for the indications on their labeling.

Not as an established treatment. Studies of TMS for anorexia nervosa, bulimia nervosa, and binge eating disorder are small and early-stage, with inconsistent findings, and no device is FDA-cleared for any eating disorder. Marketing that suggests otherwise is not supported by evidence. Eating disorders are best treated by specialized programs combining nutritional rehabilitation, psychotherapy, and medical monitoring; TMS should be considered only within a research study.

In adults with major depression, standard TMS protocols stimulate the left dorsolateral prefrontal cortex, a region involved in regulating both mood and worry. Trials measuring anxiety scales in depressed patients found anxiety symptoms improved along with depression, which supported the anxious-depression clearances. The same course of about 30 to 36 sessions addresses both; there is no separate anxiety protocol. Because the evidence comes from people with depression, this does not establish that TMS treats anxiety disorders in people without depression.